Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs

Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2015.07.010
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Elsevier BV

Related search

Targeted Therapy for Renal Cell Carcinoma

2011English

The Bevacizumab Experience in Advanced Renal Cell Carcinoma

OncoTargets and Therapy
OncologyPharmacology
2010English

Clinical Impact of Targeted Therapies in Patients With Metastatic Clear-Cell Renal Cell Carcinoma

OncoTargets and Therapy
OncologyPharmacology
2014English

The Role of VHL in Clear-Cell Renal Cell Carcinoma and Its Relation to Targeted Therapy

Kidney International
Nephrology
2009English

Safety and Efficacy of Sunitinib for Advanced Non-Clear Cell Renal Cell Carcinoma

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2015English

Clear Cell Papillary Renal Cell Carcinoma

Archives of Pathology and Laboratory Medicine
MedicineForensic MedicinePathologyMedical Laboratory Technology
2019English

Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

Cancer Research and Treatment
Cancer ResearchOncology
2019English

Acanthosis Nigricans Associated With Clear-Cell Renal Cell Carcinoma

Autopsy and Case Reports
2016English

Molecular Genetics of Clear-Cell Renal Cell Carcinoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy